- American City Business Journals•10 days ago
A year after a scathing attack by an anonymous short seller thwarted plans to jump to the Nasdaq, Beverly biotech Cellceutix is hoping a new president with a big pharma background will jumpstart its transformation from a company that’s been mostly ignored by big investors into one that’s traded on the Nasdaq and has institutional shareholders. In June, Cellceutix (CTIX), which employs 14 people, named Arthur Bertolino as its first president and chief medical officer. In an interview last week at the company’s headquarters, CEO Leo Ehrlich called Bertolino — a former Novartis (NVS) and Pfizer (PFE) executive — “the new face of the company,” saying he’ll head up efforts to forge partnerships on its drugs.
- Marketwired•24 days agoCellceutix Prepares Phase 2a Ovarian Cancer Trial of Kevetrin, a Novel p53-Modulating Drug Candidate, Based Upon Phase 1 Topline Data
Cellceutix Corporation, , a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, antibiotic, and anti-inflammatory applications, is pleased to provide topline ...
- Marketwired•last month
Cellceutix Corporation, , a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, antibiotic, and anti-inflammatory applications, is pleased to provide additional......
Cellceutix Corporation (CTIX)
Other OTC - Other OTC Delayed Price. Currency in USD
|Day's Range||1.33 - 1.37|
|52wk Range||0.94 - 2.05|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||-12.61|
|Avg Vol (3m)||148,896|
|Dividend & Yield||N/A (N/A)|